The Week in Review: Jan 4, 2019 – Jan 11, 2019

Friday, Jan 11, 2019 News Recap: Winners of HepCBC’s November and December, 2019 Colouring Book Contest Announced HepCBC has a monthly contest aimed at current and former prisoners, but others are welcome to join. The prize is $50 worth of art supplies. Dramatic Series, UNSPEAKABLE about Canada’s Tainted Blood Scandal January 9, 2019, Toronto. A new CBC TV historical drama series, Unspeakable, started today which follows the lives of a couple he...

HepCBC Gets Thank-You Letter from Federal Government Agency, CADTH

Since 2011, HepCBC has provided patient group input to BC PharmaCare and, to the federal government, through CADTH – the Canadian Agency for Drugs and Technologies in Health. CADTH is one of the first ‘hoops’ new drugs and treatments must go through, while the various provincial Pharmacare plans are the final stage of approval, awarding patients coverage for the drug/treatment through the provincial health plan. You can see all the submissions HepCBC has m

The Week in Review: April 28 – May 11, 2018

Friday, May 11, 2018 News Recap: HBV: CADTH recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B. The CADTH Canadian Drug Expert Committee (CDEC) recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B in adults with compensated liver disease, if the following condition is met: CONDITION: The drug plan cost of TAF should not exceed that of the lowest-cost prepar...

BRIEF: CADTH recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B

IN BRIEF: RECOMMENDATION The CADTH Canadian Drug Expert Committee (CDEC) recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B in adults with compensated liver disease, if the following condition is met: CONDITION: The drug plan cost of TAF should not exceed that of the lowest-cost preparation of tenofovir disoproxil fumarate (TDF). Read more: https://www.cadth.ca/tenofovir-alafenamide  

The Week in Review: March 9 – March 16, 2018

Friday, March 16, 2018 News Recap: Canada: Treatment: Fantastic news from both BC and Quebec this last week:  All restrictions to treatment under the respective provincial PharmaCare plans have been removed!! See Chronic hepatitis C medication now available for all British Columbians, and Quebec Expands Patient Access to Chronic Hepatitis C Therapies. Grants Awarded to 13 Canadian Initiatives to Help Advance the Goal of Eliminating Chronic Hep...

The Week in Review: February 2 – February 9, 2018

Friday, February 9, 2018 News Recap: Epidemiology: CTAC Launches Campaign to End Hepatitis C in Canada. The Canadian Treatment Action Council (CTAC) has published a white paper entitled, "The time has come to eliminate hepatitis C in Canada," which summarizes the increasing gaps in Canada's response to the hepatitis C epidemic and identifies seven calls-to-action. #EASLmono: Expanding the conversation on hepatitis elimination. The recent European...

Attention Hepatitis B (HBV) Patients & Caregivers – Your Help Requested

Do you have HEPATITIS B or are you a CAREGIVER for someone with HBV? This is really important for you! An improved hepatitis B treatment will likely be covered by BC (Canada) PharmaCare soon, but first the BC government has requested HepCBC to submit a patient group review explaining whether hepatitis B patients want this new treatment, and why. SURVEY – ANSWER 5 QUESTIONS BELOW BY EMAIL or PHONE (English or Chinese 中文 ) HepCBC needs to hear your voice

CDEC Recommends MAVIRET™ and VOSEVI™ for Reimbursement for Chronic HCV

On January 25, 2018 the federal CADTH Canadian Drug Expert Committee (CDEC) released its extensive reviews of two new "pan-genotypic" hepatitis C treatments: Maviret™ (AbbVie) and Vosevi™ (Gilead). In both cases, the drugs were recommended for reimbursement by provincial PharmaCares for "adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis." And, for both, reimburseme...

The Week in Review: December 1 – December 8, 2017

Friday, December 8, 2017 News Recap: URGENT BC Patient and Caregiver Input Request: Vosevi. We need to hear your voice! Patient and Caregiver input is requested by BC PharmaCare on Gilead’s combo of sofosbuvir, velpatasvir, and voxilaprevir (SOF-VEL-VOX or Vosevi™) for Genotypes 1-6. Personal Stories This week we have two great stories of triumphing over HepC: Aidain’s ‘I will never forget the day I found out I had hepatitis c’, and Patric...